Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digital Monitoring of Symptoms in Advanced RCC Patients on Cabozantinib + Nivolumab (CANIQOL)
NCT07028125Phase 4Recruiting
- Sponsor
- Centre François Baclesse
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in renal cell carcinoma (RCC), sponsored by Centre François Baclesse. Primary endpoint: Rate of patients with adjustment of treatments management at 3 months. Started Oct 2025; status: recruiting.
02
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07028125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028125.